Inogen, Inc. (NASDAQ:INGN) Short Interest Update

Inogen, Inc. (NASDAQ:INGN) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 826,300 shares, a decrease of 11.4% from the October 15th total of 932,600 shares. Based on an average daily trading volume, of 190,100 shares, the short-interest ratio is presently 4.3 days.

Institutional Trading of Inogen

Hedge funds have recently modified their holdings of the business. Divisadero Street Capital Management LP grew its position in Inogen by 682.3% in the 2nd quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock worth $19,079,000 after purchasing an additional 2,046,766 shares during the last quarter. Brown Capital Management LLC lifted its stake in shares of Inogen by 26.6% in the 1st quarter. Brown Capital Management LLC now owns 1,975,312 shares of the medical technology company’s stock valued at $15,941,000 after purchasing an additional 414,903 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Inogen by 312.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock worth $1,694,000 after buying an additional 132,287 shares during the period. AQR Capital Management LLC increased its position in shares of Inogen by 29.3% in the 2nd quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock valued at $4,642,000 after buying an additional 129,307 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new stake in Inogen during the 2nd quarter worth approximately $651,000. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Inogen Stock Performance

Shares of INGN stock traded down $0.46 during mid-day trading on Monday, reaching $9.59. 121,542 shares of the company were exchanged, compared to its average volume of 332,662. The business’s 50 day simple moving average is $9.82 and its 200 day simple moving average is $9.55. Inogen has a fifty-two week low of $4.93 and a fifty-two week high of $13.33. The company has a market capitalization of $228.41 million, a P/E ratio of -4.43 and a beta of 1.04.

Analysts Set New Price Targets

INGN has been the subject of several research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a research note on Friday, November 8th. StockNews.com upgraded shares of Inogen from a “hold” rating to a “buy” rating in a report on Tuesday, November 12th.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.